Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rapid Micro Biosystems (Nasdaq: RPID) announced inducement equity awards granted February 2, 2026, to three newly hired employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) announced inducement equity awards granted February 2, 2026, to three newly hired employees.
The company granted 205,000 RSUs and 168,000 stock options under its Inducement Plan, with options priced at $4.19 per share and standard time-based vesting schedules.
The awards were approved by a majority of independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – RPID
On Feb 13, the first trading day after this news, RPID closed 2.76% above the previous close.
Data tracked by StockTitan Argus for the Feb 13 session.
Key Figures
- RSU grants
- 205,000 RSUs
- Inducement awards to three new employees
- Stock options granted
- 168,000 options
- Inducement awards to three new employees
- New employees
- 3 employees
- Recipients of inducement equity grants
- Option exercise price
- $4.19 per share
- Equal to closing price on grant date
- Initial option vesting
- 25%
- Vests on first anniversary of grant date
- Ongoing option vesting
- 1/48th per month
- Monthly vesting after first anniversary
- RSU vesting period
- 3 years
- RSUs vest annually over three-year period
- Annual RSU vesting rate
- One-third per year
- RSUs vest on each anniversary of grant date
Historical Context
-
Record preliminary Q4 and full-year 2025 revenue update.
-
Announcement of presentation at J.P. Morgan Healthcare Conference.
-
$45M growth capital commitment to scale Growth Direct platform.
-
Q3 2025 results with raised full-year revenue and placement guidance.
-
Participation in Stifel 2025 Healthcare Conference with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
non-qualified stock options financial
exercise price financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on February 2, 2026, of an aggregate of 205,000 restricted stock units (“RSUs”) of the Company’s Class A common stock (“Common Stock”) and non-qualified stock options to purchase an aggregate of 168,000 shares of Common Stock (the “Options”), all as a material inducement to employment for three new employees. All such equity awards were made under the Company’s Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.
The Options have an exercise price of
The RSUs will vest annually over a three-year period, with one-third of the RSUs vesting on each anniversary of their respective grant dates, subject to such employee's continued employment on each vesting date.
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with the Company, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
About Rapid Micro Biosystems
Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.